Haneen Shalabi, D.O.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 1W5890
- Bethesda, MD 20892
Dr. Shalabi's primary research interests are novel immunotherapy targets for chemo-resistant acute lymphoblastic leukemia. Her clinical focus is the treatment of relapsed/refractory pediatric patients with hematologic malignancies utilizing chimeric antigen receptor (CAR) T cell therapies. Additional areas of interest include neurocognitive effects of immunotherapy in pediatric patients and bone marrow transplantation for patients with malignant and non-malignant diseases.
Areas of Expertise
1) pediatric leukemia 2) chimeric antigen receptor (CAR) T cell therapy for pediatric leukemia 3) immunotherapy for relapsed/refractory hematologic malignancies 4) cognitive effects post-immunotherapy
Information for Patients
Learn more about the Leukemia, Lymphoma, Transplant and Cell Therapy Team and clinical trials.
Dr. Shalabi focuses on translation of chimeric antigen receptor therapy to treat high-risk hematologic malignancies in pediatric patients. She works in conjunction with the neurobehavioral team to assess patients receiving immunotherapy for neurocognitive changes.
Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia
Cell-based Therapies: A New Frontier of Personalized Medicine
Haneen Shalabi, D.O.
Dr. Shalabi received her medical degree in 2010 from Midwestern University, Chicago College of Osteopathic Medicine. In 2013, she completed her pediatric residency in Chicago at Loyola University Medical Center, and then completed her fellowship in pediatric hematology/oncology at Children's National Medical Center in Washington DC in 2016. From 2016-2018, she joined the Pediatric Oncology Branch as an advanced studies fellow with a focus in pediatric cellular therapies.